CERS Stock Analysis: Cerus | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 476m USD | 12M Return: 54% | US1570851014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.02M
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cerus Corporation (NASDAQ: CERS) is a U.S.-based biomedical products company headquartered in Concord, California, that develops and commercializes the INTERCEPT Blood System, a proprietary pathogen reduction technology designed to enhance transfusion safety. The platform includes systems for platelets, plasma, red blood cells, and cryoprecipitated fibrinogen complex, each intended to inactivate a broad spectrum of blood-borne pathogens in donated blood components. The company also markets the INTERCEPT Illuminator, an LED-based device used to treat blood components as part of the system. Cerus sells its platelet and plasma systems through a direct sales force and distributors across the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international markets. Originally incorporated in 1991 as Cerus Technologies Inc., the company adopted its current name in July 1996 and has been publicly traded since its 1997 IPO.
Cerus operates within the GICS Health Care Supplies sub-industry, a segment that includes companies manufacturing and distributing medical devices, diagnostic products, and healthcare-related consumables. As a Small Cap stock with a market capitalization of approximately $461 million, the company sits at the smaller end of publicly listed healthcare equipment providers. Its business model is centered on selling proprietary, single-use disposable kits (pathogen reduction sets) along with reusable illuminator devices, a razor-and-blade structure that creates a recurring revenue stream tied to the volume of blood components processed by blood centers and hospitals.
- INTERCEPT platelet and plasma sales drive double-digit revenue growth
- Red blood cell system FDA approval remains key catalyst
- Cash burn and dilution risk from persistent operating losses
| Net Income: -7.31m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: 33.79% < 20% (prev 39.51%; Δ -5.71% < -1%) |
| CFO/TA 0.02 > 3% & CFO 3.50m > Net Income -7.31m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (201.7m) vs 12m ago 5.12% < -2% |
| Gross Margin: 51.83% > 18% (prev 55.19%; Δ -3.35% > 0.5%) |
| Asset Turnover: 107.9% > 50% (prev 92.57%; Δ 15.34% > 0%) |
| Interest Coverage Ratio: -0.30 > 6 (EBIT TTM -2.47m / Interest Expense TTM 8.34m) |
| A: 0.37 (Total Current Assets 156.6m - Total Current Liabilities 80.0m) / Total Assets 204.7m |
| B: -5.31 (Retained Earnings -1.09b / Total Assets 204.7m) |
| C: -0.01 (EBIT TTM -2.47m / Avg Total Assets 210.0m) |
| D: 0.59 (Book Value of Equity 76.4m / Total Liabilities 128.4m) |
| Altman-Z'' = -14.30 = D |
| DSRI: 0.90 (Receivables 30.6m/29.8m, Revenue 226.6m/199.2m) |
| GMI: 1.06 (GM 55.19% / 51.83%) |
| AQI: 0.94 (AQ_t 0.15 / AQ_t-1 0.16) |
| SGI: 1.14 (Revenue 226.6m / 199.2m) |
| TATA: -0.05 (NI -7.31m - CFO 3.50m) / TA 204.7m) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of November 04, 2026, the stock is trading at USD 2.34 with a total of 3,495,967 shares traded. Over the past week, the price has changed by -2.50%, over one month by +0.00%, over three months by +8.84% and over the past year by +53.95%.
Current recommended Stop Loss: 2.20 (which is 6% or 1.4 ATR below the current price).
Cerus has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CERS.
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.1 | 119.2% |
P/S = 2.1467
P/B = 6.5617
Revenue TTM = 226.6m USD
EBIT TTM = -2.47m USD
EBITDA TTM = -1.04m USD
Long Term Debt = 40.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 31.8m USD (from shortTermDebt, last quarter)
Debt = 84.2m USD (corrected: LT Debt 40.5m + ST Debt 31.8m) + Leases 11.9m
Net Debt = 27.1m USD (calculated: Debt 84.2m - CCE 57.1m)
Enterprise Value = 502.7m USD (475.6m + Debt 84.2m - CCE 57.1m)
Interest Coverage Ratio = -0.30 (Ebit TTM -2.47m / Interest Expense TTM 8.34m)
EV/FCF = 1000.0x (Enterprise Value 502.7m / FCF TTM 494k)
FCF Yield = 0.10% (FCF TTM 494k / Enterprise Value 502.7m)
FCF Margin = 0.22% (FCF TTM 494k / Revenue TTM 226.6m)
Net Margin = -3.23% (Net Income TTM -7.31m / Revenue TTM 226.6m)
Gross Margin = 51.83% ((Revenue TTM 226.6m - Cost of Revenue TTM 109.1m) / Revenue TTM)
Gross Margin QoQ = 52.44% (prev 51.41%)
Tobins Q-Ratio = 2.46 (Enterprise Value 502.7m / Total Assets 204.7m)
Interest Expense / Debt = 9.90% (Interest Expense 8.34m / Debt 84.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.95m (EBIT -2.47m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.96 (Total Current Assets 156.6m / Total Current Liabilities 80.0m)
Debt / Equity = 1.10 (Debt 84.2m / totalStockholderEquity, last quarter 76.4m)
Debt / EBITDA = -25.99 (negative EBITDA) (Net Debt 27.1m / EBITDA -1.04m)
Debt / FCF = 54.93 (Net Debt 27.1m / FCF TTM 494k)
Total Stockholder Equity = 69.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.48% (Net Income -7.31m / Total Assets 204.7m)
RoE = -10.52% (Net Income TTM -7.31m / Total Stockholder Equity 69.5m)
RoCE = -2.24% (EBIT -2.47m / Capital Employed (Equity 69.5m + L.T.Debt 40.5m))
RoIC = -1.34% (negative operating profit) (NOPAT -1.95m / Invested Capital 145.2m)
WACC = 9.23% (E(475.6m)/V(559.8m) * Re(9.48%) + D(84.2m)/V(559.8m) * Rd(9.90%) * (1-Tc(0.21)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.44 | Cagr: 3.91%
[DCF] Terminal Value 75.17% ; FCFF base≈364k ; Y1≈417k ; Y5≈613k
[DCF] Fair Price = N/A (negative equity: EV 7.99m - Net Debt 27.1m = -19.1m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.82 | Revenue CAGR: 14.40% | SUE: -0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS next Quarter (2027-03-31): EPS=-0.01 | Chg30d=N/A | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.04 | Chg30d=N/A | Revisions=-40% | GrowthEPS=+43.8% | GrowthRev=+20.8%
EPS next Year (2027-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+88.9% | GrowthRev=+9.0%
[Analyst] Revisions Ratio: -57% (up=0, down=4)